“Steroid-Refractory Chronic Graft-versus-Host Disease Treated with Ruxolitinib: A Narrative Review of Symptom Burden and Return to Daily Life”, JCCSR, vol. 4, no. 1, pp. 31–36, Nov. 2023, doi: 10.5281/zenodo.22227762.